BERKELEY, Calif.--Caribou Biosciences, Inc., a leading CRISPR genome editing company, today announced the appointment of Cherry Thomas, MD, as Senior Vice President of Clinical Development. In this newly created position, Dr. Thomas will serve as Caribou’s clinical leader and oversee the advancement of the Company’s first allogeneic CAR-T cell therapy candidate, expected to start clinical trials later this year.

BERKELEY, CA and RICHMOND, CA – February 19, 2020 – Caribou Biosciences, Inc., a leading CRISPR genome editing company, and ProMab Biotechnologies, Inc., a biotechnology CRO/CDMO specializing in antibody engineering and CAR-T development, today announced a sale and assignment agreement under which Caribou gains access to a ProMab humanized single-chain variable fragment (scFv) targeting the B Cell Maturation Antigen (BCMA) for use in allogeneic engineered cell therapies.